All In Biotech

Drug Trial Radar · NCT06079541

Phase 1 Clinical Study of JMKX003142 Tablets

Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Tablets Administered Randomly, Double-blind, Placebo-controlled Single and Multiple Times in Healthy Adult Subjects, as Well as the Effects of Randomized, Open, and Two Cycle Crossover Foods

Last checked: Nov 19, 2026Latest source record: Oct 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

106

Planned (sponsor's estimate)

Start

Jul 6, 2023

Primary completion

Jul 31, 2024

Study completion Mar 30, 2025

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of JMKX003142 tablets administered randomly, double-blind, placebo-controlled single and multiple times in healthy adult subjects, as well as the effects of randomized, open, and two cycle crossover foods

Conditions

  • Safety and Tolerability

Interventions

  • JMKX003142 will be administered orallyDrug

    oral once

  • JMKX003142 will be administered orallyDrug

    oral once

  • JMKX003142 will be administered orallyDrug

    oral once

  • Placebo in Cohorts 1 to 7Drug

    oral once

  • Placebo in 3 CohortsDrug

    oral once

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of the Adverse Events that are related to the single dose treatmentTime frame: from baseline to Day 18
  2. Number of the Adverse Events that are related to the multiple dose treatment fromTime frame: from baseline to Day 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.